Literature DB >> 7718887

BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia.

J Diamond1, J M Goldman, J V Melo.   

Abstract

It has been suggested that the BCR-ABL gene of chronic myeloid leukemia (CML) is not uniformly expressed in Philadelphia (Ph)-positive cells, and that BCR-ABL gene expression precludes transcription of the normal BCR or ABL genes. Therefore, we have analyzed granulocyte-macrophage colony-forming unit (CFU-GM) colonies derived from peripheral blood of 11 CML patients by cytogenetic and by reverse transcriptase-polymerase chain reaction (PCR) amplification of BCR-ABL, ABL-BCR, BCR, and ABL. All CFU-GM colonies with analyzable metaphases were found to contain a Ph chromosome. In 2 patients, the initial PCR screening failed to detect BCR-ABL transcripts in 2 of 11 and 1 of 7 Ph-positive colonies. However, when amplification for BCR-ABL was repeated in quintuplicate, all but 1 colony from a single patient showed one or more positive results. Amplifications of the four genes in each colony showed that BCR-ABL, ABL-BCR, and the normal BCR and ABL were simultaneously expressed in the majority of CFU-GM colonies. Replicate PCR tests for BCR and for ABL in colonies initially scored as negative also uncovered previously undetected positive amplifications. We conclude that BCR-ABL expression does not suppress transcription from the normal BCR and ABL genes, and that Ph-positive, BCR-ABL-negative colonies derived from peripheral blood CFU-GM are rare or nonexistent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7718887

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Authors:  Yashodhara Dasgupta; Mateusz Koptyra; Grazyna Hoser; Kanchan Kantekure; Darshan Roy; Barbara Gornicka; Margaret Nieborowska-Skorska; Elisabeth Bolton-Gillespie; Sabine Cerny-Reiterer; Markus Müschen; Peter Valent; Mariusz A Wasik; Christine Richardson; Oliver Hantschel; Heiko van der Kuip; Tomasz Stoklosa; Tomasz Skorski
Journal:  Blood       Date:  2016-02-10       Impact factor: 22.113

2.  Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.

Authors:  T Era; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

3.  Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele.

Authors:  Anna Virgili; Mateusz Koptyra; Yashodhara Dasgupta; Eliza Glodkowska-Mrowka; Tomasz Stoklosa; Elisabeth P Nacheva; Tomasz Skorski
Journal:  Cancer Res       Date:  2011-06-21       Impact factor: 12.701

4.  BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.

Authors:  Daniel W Sherbenou; Oliver Hantschel; Ines Kaupe; Stephanie Willis; Thomas Bumm; Lalita P Turaga; Thoralf Lange; Kim-Hien Dao; Richard D Press; Brian J Druker; Giulio Superti-Furga; Michael W Deininger
Journal:  Blood       Date:  2010-06-02       Impact factor: 22.113

Review 5.  Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia.

Authors:  Vivian G Oehler; Jerald P Radich
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

6.  Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.

Authors:  J S Khorashad; S K Tantravahi; D Yan; C C Mason; Y Qiao; A M Eiring; K Gligorich; T Hein; A D Pomicter; A G Reid; T W Kelley; G T Marth; T O'Hare; M W Deininger
Journal:  Leukemia       Date:  2016-08-02       Impact factor: 11.528

Review 7.  Mechanisms of receptor tyrosine kinase activation in cancer.

Authors:  Zhenfang Du; Christine M Lovly
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.